We explored the role of interleukin-7 (IL-7) in the bone marrow (BM) stroma-mediated survival of primary T-cell acute lymphoblastic leukemia (T-ALL) cells and normal thymocytes. We present evidence that IL-7 has a major role in the enhanced survival mediated by BM stroma both in T-ALL cells and thymocytes. Haematologica 2007; 92: 264-266 
To explore the mechanisms involved in the enhanced survival mediated by BM stroma, we cultured primary T-ALL cells or normal human thymocytes in vitro with either human BM stromal cells obtained from seven healthy donors, as previously described, 8 or the murine M2-10B4 fibroblast-like cell line of BM stromal origin (kindly provided by Dr Connie J Eaves, Terry Fox Laboratories, Vancouver, Canada). T-ALL cells were derived from enriched leukemic cells isolated from adult patients and classified according to their maturation stage by immunophenotypic analysis (Table 1) , as previously described. 9 T-ALL cells were considered positive for a defined antigen if at least 30% of cells were positive compared to the isotype-matched control. Thymocytes were derived from normal thymuses of children (<5 years of age) undergoing cardiac surgery. BM stroma induced a significant increase of survival in both T-ALL cells and thymocytes ( Figure 1A and 1B), as measured by annexin Vfluoroscein isothiocyanate/propidium iodide staining (Bender Med System, Vienna, Austria) and flow cytometry (FACSCalibur, Becton Dickinson, Palo Alto, CA, USA). The enhanced survival was maintained throughout the period of observation ( Figure 1C and D) . BM stroma also induced proliferation in all T-ALL cases, but not in thymocytes, as assessed by thymidine-incorporation microassay after culture with 4000-rad irradiated stromal cells ( Figure  1E ). The proliferative response of T-ALL was maintained Figure 1F ). In contrast, neither BM stroma nor M2-10B4 induced significant proliferation in normal thymocytes at any time point considered (days 2, 3, and 8; data not shown) and at different thymocyte:stromal cell ratios (ranging from 0.1:1 to 10:1). Comparable levels of survival and proliferation were observed when cells from the same patient were cultured with BM stromal cells from different donors (data not shown). We next investigated the functional role of the interaction between IL-7 and its receptor (IL-7R) in the BMinduced survival of T-ALL cells or thymocytes. BM stroma produced IL-7, as evaluated by analyzing supernatants from four independent cultures by an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) (0.8±0.3, 1.4±0.8, 2.1±0.8, 3.3±1.2 pg/mL±SD at days 1, 3, 5, and 7, respectively). All T-ALL cells and thymocytes expressed the IL-7Rα chain (CD127) (Figure 2A ) and showed a significant response to recombinant human IL-7 (10 ng/mL, Calbiochem, Merck Biosciences, Darmstadt, Germany), as determined by increased survival revealed by annexin V/propidium iodide analysis ( Figure 2B and 2C) . Functional blockage of IL-7 or IL-7Rα with antibodies (10 µg/mL, rabbit polyclonal, Biosource International, Camarillo, CA, USA; and monoclonal R34.34, Immunotech, Marseille, France, respectively) during co-cultures significantly decreased the BM-induced survival in both T-ALL cells and thymocytes with respect to control isotype-matched antibodies ( Figure 2D ). Time course analysis revealed that maximum inhibition of survival occurred after 1 day of co-culture and the effects decreased with time (data not shown). Furthermore, IL-7 or IL-7Rα blockage reduced BMinduced T-ALL proliferation (30% reduction, data not shown). However, as proliferation also depends on cell viability, it is difficult to dissect out the direct effects of IL-7/IL7R blockage from the consequences of reduced cell viability.
In summary our data indicate that (i) BM stromal cells inhibited apoptosis in both human T-ALL and thymocytes, thus extending previous data; 1,2,10 (ii) BM stromal cells induced proliferation in T-ALL cells but not in normal thymocytes; (iii) the enhanced survival mediated by BM stroma in both T-ALL cells and thymocytes required the IL-7/IL-7R interaction. However, IL-7/IL-7R blockade only partially inhibited survival, thus suggesting the existence of other mechanisms acting in co-operation with IL-7. Interestingly, it has been reported that LFA-1 and Eselectin are required, although not alone sufficient, for BM-mediated T-ALL survival.
2 Furthermore, the effects of anti-IL-7/IL-7R antibodies on T-ALL and thymocyte survival decreased with time, which could suggest that other cellular events, triggered by IL-7 but acting later on independently of it, could be involved. Taken together, these findings suggest that a complex signaling pathway involving IL-7 activity mediates BM-induced enhanced survival of T-ALL and thymocytes.
In conclusion, our findings support the notion that IL-7 can contribute to the expansion of T-ALL within the BM microenvironment. Furthermore, they highlight a property of BM stromal cells that could be relevant during early human T-cell lymphopoiesis.
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